Careful, plain-language answers about what Geneprint is, what it isn't, and how your information is protected throughout.
About the programme
No. Geneprint is a risk-assessment and prevention programme designed for healthy individuals. It is not a diagnostic test and is not intended to detect existing cancer.
No. Geneprint personalises established screening — such as mammography or colonoscopy — based on your individual risk profile. It never replaces recommended national or clinical screening guidelines.
Geneprint is only available through approved Geneprint Partner Hospitals. It is a hospital-delivered clinical programme, not a direct-to-consumer test, and every step is overseen by trained clinical staff.
No. No test or programme can guarantee this. Geneprint estimates risk and personalises prevention and screening based on the best available evidence — your report explicitly states the limitations of what it can and cannot tell you.
Geneprint is not designed for people with active or concerning symptoms. If this applies to you, please contact your hospital directly for clinical assessment rather than waiting for this programme.
About testing & results
No. Whole-genome sequencing is performed once. Annual reassessment reinterprets your existing genomic data in light of updated clinical evidence — it does not require resequencing.
Yes. A single venipuncture collects several tubes in one appointment, standardised across all partner hospitals, supporting whole-genome sequencing, clinical laboratory testing, proteomics and metabolomics.
Turnaround depends on your hospital and its laboratory partners. Your hospital will confirm an expected timeframe when you begin the programme.
An authorised Geneprint or hospital physician reviews and approves every report before release. Specialists are involved when required. AI supports this analysis but never replaces clinical review.
No. Annual reassessment is optional. Your hospital will recommend it based on your baseline findings, risk level, screening outcomes and any relevant clinical changes.
It is a genetic change whose effect on cancer risk is not yet well understood. It is never used to recommend major preventive procedures, and it does not mean you have a hereditary cancer syndrome. These variants are monitored and may be reclassified as evidence evolves.
Privacy & access
It is reviewed by your supervising physician and, where appropriate, referred to a genetic counsellor or specialist. Because such findings can affect biological relatives, a structured family prevention pathway may also be offered.
Yes, potentially. Genomic findings can have implications for biological relatives, which is why your consent process and the optional family prevention pathway both address this directly before testing begins.
Your data is encrypted in transit and at rest, access is role-based, identifiable and molecular data are separated where possible, complete audit logs are maintained, and retention periods and hosting are aligned to jurisdiction-specific requirements. See our clinical governance page for more detail.